Related Experiment Video
Updated: Jan 7, 2026

10:25
Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
Published on: November 3, 2014
34.4K
Lowly Expressed Toxin Transcripts in Poorly Characterized Myanmar Russell's Viper Venom Gland.
Khin Than Yee1, Jason Macrander2, Olga Vasieva3
1Experimental Medicine Research Division, Department of Medical Research, Yangon 11191, Myanmar.
Biotech (Basel (Switzerland))
|December 24, 2025
Summary
Researchers identified eight new Russell's viper (Daboia siamensis) venom gene families in Myanmar. These toxins may offer future therapeutic potential for conditions like cancer and antibiotic-resistant infections.
Area of Science:
- Biochemistry
- Genomics
- Toxicology
Background:
- Russell's viper (Daboia siamensis) bites pose a significant public health challenge in Myanmar.
- Understanding venom composition is crucial for developing effective antivenoms and therapeutics.
Purpose of the Study:
- To characterize candidate toxin genes from the Myanmar Russell's viper using RNA-sequencing.
- To identify novel venom gene families and predict their functions for potential therapeutic applications.
Main Methods:
- mRNA extraction from Myanmar Russell's viper venom glands.
- Illumina next-generation RNA sequencing and analysis using the Venomix pipeline.
- Bioinformatic analysis of translated protein sequences for conserved motifs and domains.
Main Results:
- Identification of 29 unique cDNA sequences belonging to eight newly discovered venom gene families.
- These transcripts represent low-to-moderate expression levels (0.088% of total).
- Identified gene families include neprilysins, cystatins, waprin, vipericidin, veficolin, vespryns, three-finger toxins, and endothelial lipases.
Conclusions:
- The study expands the known repertoire of Russell's viper toxins.
- Newly identified toxins like cystatins and antimicrobial peptides warrant further investigation for therapeutic uses.
- Potential applications include treatments for cancer and antibiotic-resistant infections.

